17,261 trials
Post Operative Pain
Primary: SPID-12 — 2.87; 1.28; 12.66; -7.39 units on a scale — p=0.194
Renal Cell Carcinoma
Primary: Progression-free Survival — 12 Weeks
Stroke · Impaired Upper Extremity Function
Primary: Fugl-Meyer Test of Motor Function — 1.9; .8; 1.3; .8 units on a scale
Accelerated Phase Chronic Myelogenous Leukemia · Blastic Phase Chronic Myelogenous Leukemia · Childhood Acute Lymphoblastic Leukemia in Remission
Primary: Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28. — 20; 8 participants
Hypertension
Primary: Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) — -4.2; -2.4; -3.1; -0.2 mm Hg…
Stomach Neoplasm
Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants
HIV-Associated Lipodystrophy Syndrome · Insulin Resistance · HIV Infections
Primary: Change in Insulin Sensitivity — 0.20; 1.44; -0.63; 0.14 uU*10^-4*min*ml^-1
Posterior Blepharitis
Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03
Irritable Bowel Syndrome
Primary: Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo — 2.72; 2.22 units on a scale — p=.001
Extensive Stage Small Cell Lung Cancer · Lung Metastases · Malignant Pleural Effusion
Primary: Progression-free Survival Rate at 12 Weeks — 26 percentage of participants
Lymphoma
Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1) — 0.185; 0.156; 1.24; 1.24 Liters
B-cell Chronic Lymphocytic Leukemia · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue · Malignant Neoplasm
Primary: Objective Overall Response Rate — 28.1; 53.8; 11.1 percentage of participants
B-cell Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart — 0 participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean Pulse Rate Over 0 to 6 Hours Post-dose at Day 28 — 1.4; 0.9 Beats per minutes (bpm)